Evidência dos Modificadores do Sistema Renina-Angiotensina na Prevenção da Enxaqueca Episódica

Autores

DOI:

https://doi.org/10.24950/R/190/20/1/2021

Palavras-chave:

Inibidores da Enzima Conversora de Angiotensina, Perturbações de Enxaqueca/prevenção e controlo

Resumo

Introdução: A enxaqueca é uma doença frequente e incapacitante. Modelos experimentais sugerem uma relação entre o sistema renina-angiotensina e o desenvolvimento de enxaqueca. Este artigo tem como objetivo rever a evidência dos inibidores deste sistema na redução da frequência dos episódios de enxaqueca.

Métodos: Foi efetuada a pesquisa de normas de orientação clínica (NOC), de revisões sistemáticas (RS) e meta-análises (MA), bem como de ensaios clínicos aleatorizados (ECA). O nível de evidência e forças de recomendação foram atribuídos recorrendo à escala Strength of Recommendation Taxonomy (SORT).

Resultados: Foram identificados 63 artigos, tendo sido selecionados oito: quatro NOC, duas RS/MA e duas RS.

Discussão/Conclusão: O tratamento preventivo da enxaqueca episódica pode ser efetuado com candesartan 16 mg/ dia (FR B), embora ainda não seja recomendado como fármaco de primeira linha. O lisinopril também mostrou potencial na prevenção da enxaqueca episódica (FR B).

Downloads

Não há dados estatísticos.

Referências

Global Burden of Disease 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:954–76

Ha H, Gonzalez A. Migraine headache prophylaxis. Am Fam Physician. 2019;99:17-24.

Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16: 86–92.

Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2013;33:629-808

Pringsheim T, Davenport WJ, Mackie G, Worthington I, Aubé M, Christie SN, et al. Canadian Headache Society Guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39:S1-59.

Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One. 2015;10:e0130733

Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain. 2019;20:57.

Touche RL, Pérez JJ, Acosta AP, Campodónico LG, García SM, Juárez DA, et al. Is aerobic exercise helpful in patients with migraine? A systematic review and meta-analysis. Scand J Med Sci Sports. 2020;30(6):965-82.

Diener HC, Gendolla A, Feuersenger A, Evers S, Straube A, Schumacher H et al. Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. Cephalalgia. 2009;29:921-7.

Scottish Intercollegiate Guidelines Network (SIGN). Pharmacological management of migraine. Edinburgh: SIGN; 2018. (SIGN publication no. 155). [consultado Jun 2020] Disponível em: http://www.sign.ac.uk

Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78: 1337-45.

Dorosch T, Ganzer CA, Lin M, Seifan A. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults. Curr Pain Headache Rep. 2019;23:85.

Ripa P, Omello R, Pistoia F, Carolei A, Sacco S. The renin–angiotensin system: a possible contributor to migraine pathogenesis and prophylaxis. Expert Rev. Neurother. 2014;14:1043–55.

Fusayasu E, Kowa H, Takeshima T, Nakaso K, Nakashima K. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain. 2007;128:209-14.

Adelborg K, Szépligeti SK, Holland-Bill L, Ehrenstein V, Horváth-Puhó E, Henderson VW et al. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ. 2018;360:k96.

Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369:1208-19.

Rist PM, Winter AC, Buring JE, Sesso HD, Kurth T. Migraine and the risk of incident hypertension among women. Cephalalgia 2018;38:1817-24.

Entonen AH, Suominen SB, Korkeila K, Mäntyselkä PT, Sillanmäki LH, Ojanlatva A, et al. Migraine predicts hypertension--a cohort study of the Finnish working-age population. Eur J Public Health. 2014;24:244-8.

Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014;34:523-32

Ebell MH, Siwek J, Weiss BD, Woolf SH, Jeffrey S, Ewingman B, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician. 2004;69:548-56.

Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289:65-9.

Toward Optimized Practice (TOP). Primary care management of headache in adults – Clinical Practice Guideline. Alberta: TOP; 2016. 2nd ed. [consultado Jun 2020] Disponível em: https://actt.albertadoctors.org/CPGs/Lists/CPGDocumentList/Primary-Care-Management-of-Headache-in-Adults.pdf

Schrader H, Stovner LJ, Helde G, Trond Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ. 2001;322: 19.

Sarchielli P, Granella F, Prudenzano MP, Pini LA, Guidetti V, Bono G, et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain. 2012;13:S31-70.

Schuh-Hofer S, Flach U, Meisel A, Israel H, Reuter U, Arnold G. Efficacy of lisinopril in migraine prophylaxis-an open label study. Eur J Neurol. 2007;14:701-3.

Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol. 2009;16:968-81.

Kouremenos E, Arvaniti C, Constantinidis TS, Giannouli E, Fakas N, Kalamatas T et al. Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine J Headache Pain. 2019;20(1),113.

Paterna S, di Pasquale P, Martino S, Arrostuto A, Ingurgio NC, Parrinello G, et al. Captopril versus placebo in the prevention of hemicrania without aura. A randomized double-blind study. Clin Ter. 1992;141:475-81.

Sonbolestan SA, Heshmat K, Javanmard SH, Saadatnia M. Efficacy of enalapril in migraine prophylaxis: a randomized, double-blind, placebo-controlled trial. Int J Prev Med. 2013;4:72-7.

Shamliyan TA, Choi JY, Ramakrishnan R, Miller JB, Wang SY, Taylor FR, et al. Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med. 2013;28:1225-37

Minervini MG, Pinto K. Captopril relieves pain and improves mood depression in depressed patients with classical migraine. Cephalalgia. 1987;7:485–6.

Sassi KLM, Martins LB, de Miranda AS, Teixeira AL. Renin-angiotensin-aldosterone system and migraine: a systematic review of human studies. Protein Pept Lett. 2020;27:512-9.

Montgomery L. Are angiotensin-converting enzyme (ACE) inhibitors effective in preventing migraine in nonhypertensive patients? J Fam Pract. 2001;50:299.

Charles JA, Jotkowitz S, Byrd LH. Prevention of migraine with olmesartan in patients with hypertension/prehypertension. Headache. 2006;46:503-7.

Park H-J, Lee S-T, Kim M. Inhibitory control of angiotensin converting enzyme by ramipril in migraine. Neurol Asia. 2013;18:289–91.

Bessaguet F, Magy L, Desmoulière A, Demiot C. The therapeutic potential of renin angiotensin aldosterone system (RAAS) in chronic pain: from preclinical studies to clinical trials. Expert Rev Neurother. 2016;16:331-9.

Downloads

Publicado

20-09-2021

Como Citar

1.
Carneiro Alves S, Santos JA, Ramos Rodrigues C, Moura A. Evidência dos Modificadores do Sistema Renina-Angiotensina na Prevenção da Enxaqueca Episódica. RPMI [Internet]. 20 de Setembro de 2021 [citado 3 de Julho de 2022];28(1):59-65. Disponível em: https://revista.spmi.pt/index.php/rpmi/article/view/89

Edição

Secção

Artigos de Revisão